People who regularly use psychoactive substances report experiencing a variety of negative impacts since the COVID-19 pandemic began, including increased use and fear of relapse or overdose, highlighting the need for improved supports and services, including better access to safe supply programs, according to a new CAMH survey published in the International Journal of Drug Policy.